GSK plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Emma Walmsley |
|||
b) |
Position/status |
Chief Executive Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
467 |
|
||
|
£15.5640 |
699 |
|
||
|
£15.5640 |
1,161 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
2,327 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Hal Barron |
|||
b) |
Position/status |
Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 January 2024 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$39.6400 |
231 |
|
||
|
$39.6400 |
365 |
|
||
|
|
|
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
596 $39.6400 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Diana Conrad |
|||
b) |
Position/status |
Chief People Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
67 |
|
||
|
£15.5640 |
109 |
|
||
|
£15.5640 |
211 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
387 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
James Ford |
|||
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
81 |
|
||
|
£15.5640 |
135 |
|
||
|
£15.5640 |
205 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
421 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Sally Jackson |
|||
b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
41 |
|
||
|
£15.5640 |
63 |
|
||
|
£15.5640 |
127 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
231 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Luke Miels |
|||
b) |
Position/status |
Chief Commercial Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
126 |
|
||
|
£15.5640 |
229 |
|
||
|
£15.5640 |
495 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
850 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Shobie Ramakrishnan |
|||
b) |
Position/status |
Chief Digital and Technology Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 January 2024 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$39.6400 |
22 |
|
||
|
$39.6400 |
96 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
118 $39.6400 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
David Redfern |
|||
b) |
Position/status |
President Corporate Development |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
99 |
|
||
|
£15.5640 |
152 |
|
||
|
£15.5640 |
286 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
537 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Regis Simard |
|||
b) |
Position/status |
President, Global Supply Chain |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
75 |
|
||
|
£15.5640 |
138 |
|
||
|
£15.5640 |
230 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
443 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Phil Thomson |
|||
b) |
Position/status |
President, Global Affairs |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
58 |
|
||
|
£15.5640 |
96 |
|
||
|
£15.5640 |
150 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
304 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Deborah Waterhouse |
|||
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
119 |
|
||
|
£15.5640 |
101 |
|
||
|
£15.5640 |
366 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
586 £15.5640 |
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Tony Wood |
|||
b) |
Position/status |
Chief Scientific Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s)
|
|
Price(s) |
Volume(s) |
|
|
£15.5640 |
173 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2024-01-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Emma Walmsley |
||||
b) |
Position/status |
Chief Executive Officer |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GSK plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2024 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
e) |
Date of the transaction |
2024-01-15 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |